SteadyMed Ltd.
SteadyMed Ltd., a pioneering biopharmaceutical company headquartered in the United States, focuses on developing innovative drug delivery solutions. Founded in 2010, the company has made significant strides in the industry, particularly in the realm of injectable medications. SteadyMed's core offerings include its proprietary drug delivery platform, which enhances the efficacy and convenience of treatments for chronic conditions. This unique technology positions the company as a leader in the biopharmaceutical sector, catering to patients who require reliable and effective medication administration. With a commitment to improving patient outcomes, SteadyMed has achieved notable milestones, including successful clinical trials and partnerships that bolster its market presence. As it continues to expand its operational reach, SteadyMed Ltd. remains dedicated to advancing healthcare through innovative solutions.
DitchCarbon Score
How does SteadyMed Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
SteadyMed Ltd.'s score of 25 is lower than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
SteadyMed Ltd.'s reported carbon emissions
SteadyMed Ltd., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of United Therapeutics Corporation, which may influence its climate commitments and reporting practices. While there are no documented reduction targets or climate pledges from SteadyMed Ltd., it is important to note that emissions data and sustainability initiatives may be inherited from its parent company, United Therapeutics Corporation. This relationship could potentially align SteadyMed with broader corporate sustainability goals, although specific details on emissions or targets are not available at this time. As a part of the pharmaceutical industry, SteadyMed Ltd. operates within a sector increasingly focused on reducing carbon footprints and enhancing environmental responsibility. However, without specific data or commitments, the company's current climate impact remains unclear.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
SteadyMed Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
